BioCardia, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-15$1.56 RISE2026-02-04$1.09 PEAK2026-03-02$1.35 138d | -30.1% 112d | Missed | Missed | — | — | +23.9% 26d | Missed |
DROP2025-09-11$2.27 RISE2025-12-30$1.18 PEAK2026-01-12$1.42 123d | -48.0% 110d | Missed | Missed | — | — | +20.3% 13d | Missed |
DROP2025-07-23$2.40 RISE2025-11-17$1.22 PEAK2025-12-04$1.47 134d | -49.2% 117d | Missed | Missed | — | — | +20.5% 17d | Missed |
DROP2025-05-14$2.77 RISE2025-09-22$1.11 PEAK2025-10-15$1.56 154d | -59.9% 131d | Missed | Missed | — | — | +40.5% 23d | Missed |
DROP2025-04-30$3.14 RISE2025-08-11$1.68 PEAK2025-09-11$2.27 134d | -46.5% 103d | Missed | Missed | — | — | +35.1% 31d | Missed |
DROP2025-04-30$3.14 RISE2025-08-07$1.68 PEAK2025-09-11$2.27 134d | -46.5% 99d | Missed | Missed | — | — | +35.1% 35d | Missed |
DROP2025-04-30$3.14 RISE2025-06-30$1.95 PEAK2025-07-10$2.42 71d | -37.9% 61d | Missed | Missed | — | — | +24.1% 10d | Missed |
DROP2025-02-14$2.84 RISE2025-04-21$1.75 PEAK2025-04-30$3.14 75d | -38.4% 66d | Missed | Missed | — | — | +79.4% 9d | Missed |
DROP2025-02-14$2.84 RISE2025-02-28$2.01 PEAK2025-04-30$3.14 75d | -29.2% 14d | Missed | Missed | — | — | +56.2% 61d | Missed |
DROP2024-08-29$4.02 RISE2024-12-19$1.84 PEAK2025-02-14$2.84 169d | -54.2% 112d | Missed | Missed | — | — | +54.3% 57d | Missed |
DROP2024-08-29$4.02 RISE2024-11-15$1.85 PEAK2025-02-14$2.84 169d | -54.0% 78d | Missed | Missed | — | — | +53.5% 91d | Missed |
DROP2024-05-21$6.15 RISE2024-08-28$2.20 PEAK2024-08-29$4.02 100d | -64.2% 99d | Missed | Missed | — | — | +82.7% 1d | Missed |
DROP2023-11-14$16.05 RISE2024-02-08$6.00 PEAK2024-03-01$8.70 108d | -62.6% 86d | Missed | Missed | — | — | +45.0% 22d | Missed |
DROP2023-11-14$16.05 RISE2023-12-13$8.10 PEAK2023-12-27$10.20 43d | -49.5% 29d | Missed | Missed | — | — | +25.9% 14d | Missed |
DROP2023-07-11$42.75 RISE2023-10-31$5.55 PEAK2023-11-14$16.05 126d | -87.0% 112d | Missed | Missed | — | — | +189.2% 14d | Missed |
1–15 / 32 1 / 3 | |||||||
No scored news yet for a sentiment trend.
Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events
Peter Altman: Thank you. This is a significant unmet clinical need for which we have FDA breakthrough designation and Medicare reimbursement at $20,000 per treatment procedure today. First, the blinded echocardiography data from the CardiAMP Heart Failure trial presented at the Technology and Heart Failure Therapeutics Conference in Boston in early March was excellent.
Moby summary of BioCardia, Inc.'s Q1 2026 earnings call
BioCardia Inc (BCDA) reports significant progress with FDA and Japanese regulatory advancements, alongside effective cost control measures despite financial challenges.
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call May 15, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman - CEO,...
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2026 First Quarter Financial Results and Business Update
BioCardia Q1 2026 earnings miss with EPS of -$0.21 overshadowed clinical progress. Stock down 0.8% pre-market amid focus on cash burn and trial advancements.
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 64.41 percent increase over losses of $(0.59) per share from the
SUNNYVALE, Calif., May 15, 2026 -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today...
SUNNYVALE, Calif., May 11, 2026 -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced...
BioCardia Inc: BioCardia Inc - FDA agrees on two pathways for Helix marketing clearance, no safety concerns raised BioCardia and FDA align on Helix transendocardial delivery catheter clearance...
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the outcome of its Pre-Submission Meeting
SUNNYVALE, Calif., April 28, 2026 -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today...
SUNNYVALE, Calif., April 20, 2026 -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today...
April 20, 2026 - BioCardia And Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure April 20, 2026 ...
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BCDA | -16.22% | -31.11% | -25.60% | -56.94% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -19.19% | -25.40% | -22.16% | -69.63% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 13.9K | $16.82K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | -0.17 | -0.21 | -23.53% |
| 2026-03-24 | -0.20 | -0.06 | +70.00% |
| 2025-11-12 | -0.25 | -0.24 | +4.00% |
| 2025-08-11 | -0.50 | -0.40 | +20.00% |
| 2025-05-14 | -0.39 | -0.59 | -51.28% |
| 2025-03-26 | -0.87 | -0.25 | +71.26% |
| 2024-11-13 | -1.19 | -0.61 | +48.74% |
| 2024-08-13 | -0.10 | -0.88 | -780.00% |
| 2024-03-27 | -1.50 | -1.35 | +10.00% |
| 2023-11-08 | -1.65 | -1.80 | -9.09% |
| 2023-08-09 | -2.55 | -2.55 | — |
| 2023-05-10 | -1.95 | -2.55 | -30.77% |
| 2023-03-29 | -3.30 | -2.40 | +27.27% |
| 2022-11-09 | -3.15 | -2.55 | +19.05% |
| 2022-08-10 | -6.30 | -2.10 | +66.67% |
| 2022-05-11 | -2.40 | -2.85 | -18.75% |